Literature DB >> 20599770

86Rb+ efflux mediated by alpha4beta2*-nicotinic acetylcholine receptors with high and low-sensitivity to stimulation by acetylcholine display similar agonist-induced desensitization.

Michael J Marks1, Natalie M Meinerz, Robert W B Brown, Allan C Collins.   

Abstract

The nicotinic acetylcholine receptors (nAChR) assembled from alpha4 and beta2 subunits are the most densely expressed subtype in the brain. Concentration-effect curves for agonist activation of alpha4beta2*-nAChR are biphasic. This biphasic agonist sensitivity is ascribed to differences in subunit stoichiometry. The studies described here evaluated desensitization elicited by low concentrations of epibatidine, nicotine, cytisine or methylcarbachol of brain alpha4beta2-nAChR function measured with acetylcholine-stimulated (86)Rb(+) efflux from mouse thalamic synaptosomes. Each agonist elicited concentration-dependent desensitization. The agonists differed in potency. However, IC(50) values for each agonist for desensitization of (86)Rb(+) efflux both with high (EC(50) approximately 3 microM) and low (EC(50) approximately 150 microM) acetylcholine sensitivity were not significantly different. Concentrations required to elicit desensitization were higher that their respective K(D) values for receptor binding. Even though the two components of alpha4beta2*-nAChR-mediated (86)Rb(+) efflux from mouse brain differ markedly in EC(50) values for agonist activation, they are equally sensitive to desensitization by exposure to low agonist concentrations. Mice were also chronically treated with nicotine by continuous infusion of 0, 0.5 or 4.0mg/kg/h and desensitization induced by nicotine was evaluated. Consistent with previous results, chronic nicotine treatment increased the density of epibatidine binding sites. Acute exposure to nicotine also elicited concentration-dependent desensitization of both high-sensitivity and low-sensitivity acetylcholine-stimulated (86)Rb(+) efflux from cortical and thalamic synaptosomes. Although chronic nicotine treatment reduced maximal (86)Rb(+) efflux from thalamus, IC(50) values in both brain regions were unaffected by chronic nicotine treatment. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599770      PMCID: PMC2935307          DOI: 10.1016/j.bcp.2010.06.040

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  67 in total

1.  Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers.

Authors:  Robert W B Brown; Allan C Collins; Jon M Lindstrom; Paul Whiteaker
Journal:  J Neurochem       Date:  2007-06-15       Impact factor: 5.372

2.  Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

3.  Effects of chronic nicotine infusion on kinetics of high-affinity nicotine binding.

Authors:  R V Bhat; M J Marks; A C Collins
Journal:  J Neurochem       Date:  1994-02       Impact factor: 5.372

Review 4.  Nicotine and behavioral sensitization.

Authors:  Danyan Mao; Daniel S McGehee
Journal:  J Mol Neurosci       Date:  2009-08-11       Impact factor: 3.444

5.  Acetylcholine receptor desensitization induced by nicotine in rat medial habenula neurons.

Authors:  R A Lester; J A Dani
Journal:  J Neurophysiol       Date:  1995-07       Impact factor: 2.714

6.  Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific.

Authors:  E M Sanderson; A L Drasdo; K McCrea; S Wonnacott
Journal:  Brain Res       Date:  1993-07-23       Impact factor: 3.252

7.  Cell autonomy, receptor autonomy, and thermodynamics in nicotine receptor up-regulation.

Authors:  Raad Nashmi; Henry Lester
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

8.  An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment.

Authors:  J R Pauly; M J Marks; S D Gross; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

9.  Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.

Authors:  Michael J Marks; Charles R Wageman; Sharon R Grady; Murali Gopalakrishnan; Clark A Briggs
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

10.  Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice.

Authors:  Michael J Marks; Paul Whiteaker; Sharon R Grady; Marina R Picciotto; J Michael McIntosh; Allan C Collins
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

View more
  20 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.

Authors:  Roger L Papke; Caryn Trocmé-Thibierge; Daniela Guendisch; Shehd Abdullah Abbas Al Rubaiy; Stephen A Bloom
Journal:  J Pharmacol Exp Ther       Date:  2011-02-01       Impact factor: 4.030

3.  The additional ACh binding site at the α4(+)/α4(-) interface of the (α4β2)2α4 nicotinic ACh receptor contributes to desensitization.

Authors:  N Benallegue; S Mazzaferro; C Alcaino; I Bermudez
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

4.  Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors.

Authors:  M Grupe; A A Jensen; P K Ahring; J K Christensen; M Grunnet
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

5.  Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats.

Authors:  Morten Grupe; Giovanna Paolone; Anders A Jensen; Karin Sandager-Nielsen; Martin Sarter; Morten Grunnet
Journal:  Biochem Pharmacol       Date:  2013-09-16       Impact factor: 5.858

6.  The interaction of the Chrna5 D398N variant with developmental nicotine exposure.

Authors:  H C O'Neill; C R Wageman; S E Sherman; S R Grady; M J Marks; J A Stitzel
Journal:  Genes Brain Behav       Date:  2018-04-17       Impact factor: 3.449

7.  Rare human nicotinic acetylcholine receptor α4 subunit (CHRNA4) variants affect expression and function of high-affinity nicotinic acetylcholine receptors.

Authors:  T D McClure-Begley; R L Papke; K L Stone; C Stokes; A D Levy; J Gelernter; P Xie; J Lindstrom; M R Picciotto
Journal:  J Pharmacol Exp Ther       Date:  2014-01-02       Impact factor: 4.030

8.  Non-equivalent ligand selectivity of agonist sites in (α4β2)2α4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy.

Authors:  Simone Mazzaferro; Federica Gasparri; Karina New; Constanza Alcaino; Manuel Faundez; Patricio Iturriaga Vasquez; Ranjit Vijayan; Philip C Biggin; Isabel Bermudez
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

9.  The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype.

Authors:  J Brek Eaton; Linda M Lucero; Harrison Stratton; Yongchang Chang; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  J Pharmacol Exp Ther       Date:  2013-11-04       Impact factor: 4.030

10.  Mice expressing the ADNFLE valine 287 leucine mutation of the Β2 nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function.

Authors:  Heidi C O'Neill; Duncan C Laverty; Natalie E Patzlaff; Bruce N Cohen; Carlos Fonck; Sheri McKinney; J Michael McIntosh; Jon M Lindstrom; Henry A Lester; Sharon R Grady; Michael J Marks
Journal:  Pharmacol Biochem Behav       Date:  2012-11-01       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.